1-(2,2-Dimethyl-6-nitro-2,3-dihydro-benzo[1,4]thiazin-4-yl)-propan-2-one | 265994-74-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 1-(2,2-Dimethyl-6-nitro-2,3-dihydro-benzo[1,4]thiazin-4-yl)-propan-2-one
• 英文别名: 1-(2,2-dimethyl-6-nitro-3H-1,4-benzothiazin-4-yl)propan-2-one
• CAS: 265994-74-9
• 化学式: C₁₃H₁₆N₂O₃S
• 分子量: 280.348
• InChiKey: AEZMAYZWGSLVSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  91.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(2,2-Dimethyl-6-nitro-2,3-dihydro-benzo[1,4]thiazin-4-yl)-propan-2-one 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以91%的产率得到
  参考文献：
  名称：

  Novel potassium channel openers. Part 4: transformation of the 1,4-benzoxazine skeleton into 1,4-benzothiazine, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoxaline, indoline, and 1,5-benzoxazepine

  摘要：

  As part of a search for a new potassium channel opener, the 1,4-benzoxazine skeleton derived from the benzopyran skeleton of cromakalim, was transformed into other fused rings such as 1,4-benzothiazine, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoxaline, indoline, and 1,5-benzoxazepine. The 1,4-benzothiazine derivative displayed approximately 20 times more potent vasorelaxant activity than cromakalim. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00292-8
• 作为产物：
  描述：

  2,4-dinitrothiophenol 在 盐酸 、 sodium hydroxide 、 硼烷四氢呋喃络合物 、 草酰氯 、 硫酸 、 铁粉 、 potassium carbonate 、 copper(II) sulfate 、 二甲基亚砜 、 三乙胺 、 sodium nitrite 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.5h， 生成 1-(2,2-Dimethyl-6-nitro-2,3-dihydro-benzo[1,4]thiazin-4-yl)-propan-2-one
  参考文献：
  名称：

  Novel potassium channel openers. Part 4: transformation of the 1,4-benzoxazine skeleton into 1,4-benzothiazine, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoxaline, indoline, and 1,5-benzoxazepine

  摘要：

  As part of a search for a new potassium channel opener, the 1,4-benzoxazine skeleton derived from the benzopyran skeleton of cromakalim, was transformed into other fused rings such as 1,4-benzothiazine, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoxaline, indoline, and 1,5-benzoxazepine. The 1,4-benzothiazine derivative displayed approximately 20 times more potent vasorelaxant activity than cromakalim. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00292-8

文献信息

• [EN] BENZOTHIAZINE COMPOUNDS AS H3 RECEPTOR LIGANDS<br/>[FR] COMPOSÉS BENZOTHIAZINES EN TANT QUE LIGANDS DE RÉCEPTEUR H3
  申请人：OXYGEN HEALTHCARE RES PVT LTD

  公开号：WO2013076590A1

  公开（公告）日：2013-05-30

  The present invention provides benzothiazine derivative of formula (I), useful in the treatment of CNS disorders including cognitive disorders, ADHD, narcolepsy, pain, dementias, schizophrenia as well as obesity and sleep disorders. Pharmacological profile of these compounds includes high affinity binding with H3 receptor along with favourable selectivity profile for other aminergic receptors. The present invention also includes 'their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions.

  本发明提供了式(I)的苯并噻嗪衍生物，用于治疗包括认知障碍、注意力缺陷多动障碍、嗜睡症、疼痛、痴呆症、精神分裂症以及肥胖症和睡眠障碍在内的中枢神经系统疾病。这些化合物的药理特性包括与H3受体的高亲和结合，以及对其他胺能受体有良好的选择性特征。本发明还包括它们的类似物、它们的互变异构体、它们的立体异构体、它们的多晶形态、它们的药学上可接受的盐、它们的药学上可接受的溶剂合物和药学上可接受的组合物。
• Novel potassium channel openers. Part 4: transformation of the 1,4-benzoxazine skeleton into 1,4-benzothiazine, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoxaline, indoline, and 1,5-benzoxazepine
  作者：Yuzo Matsumoto、Ryuji Tsuzuki、Akira Matsuhisa、Toru Yoden、Yoko Yamagiwa、Isao Yanagisawa、Tadao Shibanuma、Hiroyuki Nohira

  DOI：10.1016/s0968-0896(99)00292-8

  日期：2000.2

  As part of a search for a new potassium channel opener, the 1,4-benzoxazine skeleton derived from the benzopyran skeleton of cromakalim, was transformed into other fused rings such as 1,4-benzothiazine, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoxaline, indoline, and 1,5-benzoxazepine. The 1,4-benzothiazine derivative displayed approximately 20 times more potent vasorelaxant activity than cromakalim. (C) 2000 Elsevier Science Ltd. All rights reserved.